Literature DB >> 11220982

Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology.

A M Olsson1, M J Speakman, W W Dinsmore, F Giuliano, C Gingell, M Maytom, M D Smith, I Osterloh.   

Abstract

Sildenafil citrate (Viagra) has been shown to be an effective treatment for erectile dysfunction (ED) of organic aetiology. This study assessed the efficacy and tolerability of sildenafil for treating ED of psychogenic and mixed psychogenic/organic aetiology. Men with ED of psychogenic and mixed aetiology were randomised in a double-blind, fixed-dose study to placebo (n = 95) or sildenafil 10 mg (n = 90), 25 mg (n = 85), or 50 mg (n = 81) once daily for 28 days. Efficacy was evaluated with two global efficacy questions, a patient log of erectile activity, a sexual function questionnaire and a partner questionnaire. Patients receiving sildenafil had significantly more grade 3 (hard enough for penetration) or grade 4 (fully hard) erections per week than patients receiving placebo, and a greater proportion of patients receiving sildenafil reported that treatment had improved their erections (p < 0.001). Results of the sexual function questionnaire demonstrated significant improvement for patients with ED receiving sildenafil compared with patients receiving placebo for frequency, hardness and duration of erections (p < 0.01), and for enjoyment of sexual intercourse and satisfaction with sex life (p < 0.05). The results of the partner questionnaire were consistent with the results reported by patients and showed that treatment with sildenafil was associated with significant improvement in the partners' own sex lives (p < 0.001). Adverse events were mostly mild to moderate in nature. The commonest adverse events were headache, dyspepsia, flushing, myalgia, arthralgia and flu syndrome. Discontinuations due to treatment-related adverse events were few, ranging from 1.1% to 6.2% for patients receiving different doses of sildenafil and 4.2% for patients receiving placebo. Sildenafil is an effective and well-tolerated treatment for ED of psychogenic or mixed aetiology with once-daily dosing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11220982

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  7 in total

1.  Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215.

Authors:  Deborah Watkins Bruner; Jennifer L James; Charlene J Bryan; Thomas M Pisansky; Marvin Rotman; Thomas Corbett; Joycelyn Speight; Roger Byhardt; Howard Sandler; Søren Bentzen; Lisa Kachnic; Lawrence Berk
Journal:  J Sex Med       Date:  2011-01-14       Impact factor: 3.802

2.  Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction.

Authors:  Gregory Lowe; Robert Bahnson
Journal:  Ther Adv Urol       Date:  2009-12

Review 3.  Cardiovascular safety of sildenafil.

Authors:  Diane Tran; Laurence Guy Howes
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  Effects of Two Different Dosages of Sildenafil on Patients With Erectile Dysfunction.

Authors:  Hongjun Li; Gang Bai; Xinyu Zhang; Bingbing Shi; Defeng Liu; Hui Jiang; Zhigang Ji; Matthew R Davis; Ziwen Zhu; Yujiang Fang
Journal:  Am J Mens Health       Date:  2015-12-03

Review 5.  Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction.

Authors:  R Andrew Moore; Sheena Derry; Henry J McQuay
Journal:  BMC Urol       Date:  2005-12-14       Impact factor: 2.264

6.  Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors.

Authors:  Giovanni Corona; Carlo B Giorda; Domenico Cucinotta; Piero Guida; Elisa Nada
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

Review 7.  Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.

Authors:  F Giuliano; G Jackson; F Montorsi; A Martin-Morales; P Raillard
Journal:  Int J Clin Pract       Date:  2009-11-09       Impact factor: 2.503

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.